Dymind Biotech

Shenzhen Dymind Biotechnology Co., Ltd. is a high-tech enterprise focused on the research and development, manufacturing, sales, and service of in-vitro diagnostic (IVD) medical devices and reagents. Founded in 2013, the company is headquartered in Shenzhen, China, and has grown to serve over 140 countries and regions globally. The company heavily invests in R&D, with over 40% of its staff in this area and R&D expenditure exceeding 20% of revenue. Dymind has received funding from notable investors, including Sequoia Capital China, Golden Domain Linked Fund, and Yuansheng Venture Capital.

Dymind's business model centers on developing and selling a wide range of diagnostic instruments and their corresponding reagents. The company's product lines cover hematology, point-of-care testing (POCT), immunoassay, biochemistry, coagulation, and veterinary diagnostics. A key product area is hematology analyzers, offering 3-part and 5-part differential devices that analyze whole blood to count and characterize blood cells. They have developed joint detection analyzers that combine blood count with C-reactive protein (CRP) and Serum amyloid A (SAA) tests, improving diagnostic efficiency for inflammation and infection. Their product portfolio includes compact POCT devices for small clinics and high-throughput automated workstations for large hospitals and reference labs. Many devices feature technologies like flow cytometry, laser scattering, and impedance methods for analysis and are designed for ease of use with features like touchscreen interfaces and low sample volume requirements.

The company serves a diverse client base, from small clinics and laboratories to large-scale hospitals and mobile medical units. By establishing a global sales network and overseas service centers, such as the one in Indonesia, Dymind implements a localization strategy to provide timely and professional support to its international customers. The company holds a significant market position, ranking second in the domestic hematology market in China.

Keywords: in-vitro diagnostics, IVD, hematology analyzers, point-of-care testing, POCT, immunoassay, medical devices, diagnostic reagents, flow cytometry, coagulation analyzers, veterinary diagnostics, CRP/SAA joint detection, blood cell analysis, clinical laboratory equipment, medical innovation, diagnostic solutions, automated analyzers, biochemistry analyzers, laser scattering technology, medical big data